The Effects of Pre-Existing Hyponatremia and Subsequent-Developing Acute Kidney Injury on In-Hospital Mortality: A Retrospective Cohort Study

Sung Woo Lee1,2, Seon Ha Baek1,3, Shin Young Ahn4, Ki Young Na1,3, Dong-Wan Chae1,3, Ho Jun Chin3, Sejoong Kim3*

1 Department of Internal Medicine, Seoul National University Postgraduate School, Seoul, Korea, 2 Department of Internal Medicine, Eulji General Hospital, Seoul, Korea, 3 Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, 4 Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea

* sejoong2@snu.ac.kr

Abstract

Background and Objectives
Both hyponatremia and acute kidney injury (AKI) are common and harmful in hospitalized patients. However, their combined effects on patient mortality have been little studied.

Methods
We retrospectively enrolled 19191 adult patients who were admitted for 1 year. Pre-existing hyponatremia was defined as a serum sodium level < 135 mmol/L on the first measurement of their admission. AKI was defined as a rise in serum creatinine by ≥ 26.5 μmol/L or ≥ 1.5 times of the baseline value of creatinine during the hospital stay.

Results
The prevalence of pre-existing hyponatremia was 8.2%. During a median 6.0 days of hospital stay, the incidence rates of AKI and in-hospital patient mortality were 5.1% and 0.9%, respectively. Pre-existing hyponatremia independently predicted AKI development and in-hospital mortality (adjusted hazard ratio [HR] 1.300, P = 0.004; HR 2.481, P = 0.002, respectively). Pre-existing hyponatremia and subsequent development of AKI increased in-hospital mortality by 85 times, compared to the patients with normonatremia and no AKI. In subgroup analysis, the AKI group showed higher rates of de novo hypernatremia than the non-AKI group during the admission. De novo hypernatremia, which might be associated with over-correction of hyponatremia, increased in-hospital mortality (HR 3.297, P <0.001), and patients with AKI showed significantly higher rates of de novo hypernatremia than patients without AKI (16.2% vs. 1.4%, P < 0.001, respectively).
Conclusion
Pre-existing hyponatremia may be associated with the development of AKI in hospitalized patients, and both hyponatremia and hospital-acquired AKI could have a detrimental effect on short term patient mortality, which might be related to the inappropriate correction of hyponatremia in AKI patients.

Introduction
Hyponatremia is the most common disorder of body fluid and electrolyte balance in hospitalized patients [1]. The presence of hyponatremia is hazardous since it is associated with increased risk of mortality in hospitalized patients [2], including those with heart [3] and liver [4] diseases, stroke [5], and chronic kidney disease (CKD) [6, 7]. According to recent meta-analysis, hyponatremic subjects showed a 2.6 times higher risk of death than non-hyponatremic subjects, even when the decrease in the serum sodium level was moderate [8].

Acute kidney injury (AKI) is also a common, but harmful disease [9]. As with hyponatremia, the presence of AKI is dangerous since it predicts mortality in critically or non-critically ill hospitalized patients [10, 11] and in community based patients [12]. There are several causes of AKI such as volume depletion [13] or overload [14, 15], sepsis [16], and heart [17] and liver [18] disease. Hyponatremia is also frequently developed in conditions with volume imbalances which can provoke the development of AKI [1, 19, 20]. Once AKI is developed, the chances of fluid overload and overcorrection of hyponatremia are increasing [21, 22], and thus extra-cautions for the treatment of electrolyte imbalance are warranted.

Under specific conditions such as cancer, cardiorenal syndrome, and liver transplantation, hyponatremia has been correlated with the development of AKI [23–25]. In contrast, cross-talk between pre-existing hyponatremia and hospital acquired AKI in a large cohort study has been sparsely investigated [26, 27]. Therefore, we investigated whether pre-existing hyponatremia could predict the development of AKI, and whether AKI and hyponatremia have a combined effect on patient mortality using data from an 1-year administrative cohort.

Material and Methods
Patients
We collected data from 21572 adult patients aged 18 years or older, whose serum creatinine was identified once or more during their first admission for 1 year in 2013 at a tertiary care hospital, Seongnam, Korea (Fig 1). Among these, 19592 patients were eligible for the study after excluding patients with missing sodium data (n = 453), known end stage renal disease (ESRD, n = 309) and community acquired AKI (n = 1218). Of the remaining 19592 patients, we only included 19191 patients after further excluding 401 patients with hypernatremia at admission since hypernatremia is another independent risk factor of mortality [28] and is beyond the scope of this study. The study protocol complies with the Declaration of Helsinki and received full approval from the Seoul National University Hospital’s institutional review board (IRB number: B-1511/322-112), which waived the need for informed consent since the study did not infringe on patient privacy or health status.
Definitions and measurements

Demographic, physiological, and laboratory data at the index admission were gathered from the electronic medical records database. After different patient datasets were merged, data verification was performed manually. Hypertension was defined as the presence of a physician diagnosis or receiving anti-hypertensive drugs. Anti-hypertensive drugs included alpha and beta blockers, calcium channel blockers, renin angiotensin system (RAS) inhibitors, and diuretics. Diabetes was defined as physician diagnosis or being prescribed insulin or oral anti-diabetic drugs. Cardiovascular disease was defined as a physician diagnosis of angina, ischemic heart disease, myocardial infarction or cerebrovascular disease. Body mass index was calculated as weight (kg) per square of height (m$^2$). Biochemistry analysis including serum glucose was performed using random blood or urine samples. For the inflammatory markers, we used white blood cell counts, red cell distribution width (RDW) [11], neutrophil to lymphocyte ratio (NLR) [29], and C-reactive protein (CRP).

Using the first serum sodium level of the index admission, we defined hypo- and hypernatremia as serum sodium < 135 mmol/L [1] and ≥ 145 mmol/L [30], respectively. Among 19191 patients, 18353 had serial data of serum sodium levels during their index admission. De novo hypernatremia was defined as at least one event of hypernatremia during the hospital stay. Corrected hyponatremia was defined as mean serum sodium level during hospital stay ≥ 135 mmol/L in hyponatremic patients. De novo hyponatremia was defined as cases with mean serum sodium level during hospital stay < 135 mmol/L in normonatremic patients.
When mean serum sodium levels were $\geq 135$ mmol/L in normonatremic patients and $< 135$ mmol/L in hyponatremic patients, we defined these as persistent normonatremia and hyponatremia, respectively.

Serum creatinine was measured using the rate-blanked compensated kinetic alkaline picrate Jaffe method with an automatic analyzer (Toshiba-200FR, Tokyo, Japan). The between-day coefficients of variation for serum creatinine were 1.5–2.6% and 1.1–2.4% at low (168.0–176.8 μmol/L), and high concentrations (583.4–627.6 μmol/L), respectively, throughout the study periods. The estimated glomerular filtration rate (eGFR) was calculated by using the equation of the Chronic Kidney Disease Epidemiology Collaboration [31]. Baseline creatinine was defined as the lowest value within 6 months before the index admission or the calculated value from the Modification of Diet in Renal Disease study equation, assuming GFR 75 ml/min/1.73 m$^2$ if creatinine was not available [32]. AKI was defined as a rise in serum creatinine by $\geq 26.5$ mg/dL, or $\geq 1.5$ times from the baseline level determined during the hospital stay [33, 34]. We classified a rise in serum creatinine by $\geq 2$ times from the baseline as severe AKI. If the first creatinine of the index admission met the criteria for AKI, we defined it as a community acquired AKI. In-hospital patient mortality was determined by whether a death certificate had been issued at 90 days after admission. ESRD development was determined from the registry database of the Korean Society of Nephrology, and 1 year-mortality was determined from the database of Ministry of the interior.

**Statistical analysis**

Values were expressed as mean $\pm$ SD or median (interquartile range, IQR) for continuous variables and percentage for categorical variables. The difference was analyzed by Student’s $t$ test for continuous variables and the chi-square test for categorical variables. $P$-trend was assessed by a linear-by-linear association. $P < 0.05$ was considered to have statistical significance. For the estimated survival, the Kaplan-Meier method was employed, and the statistical significance was calculated using the log-rank test. The risk of a certain factor for AKI or in-hospital mortality was assessed using Cox proportional hazard regression analysis reporting hazard ratio (HR) and its confidence interval (CI). The assumption of proportional hazards was tested by log minus log plot for categorical variables and interaction analysis with time covariate using time-dependent Cox regression for continuous variables. All covariates entered into the model fulfilled the assumption. Since known risk factors for AKI or mortality were generally statistically significant in this study, we entered variables with $P < 0.05$ in univariate analysis and missing rate $< 15\%$ into the multivariate modeling to avoid over-adjustment. The multiplicative interaction was evaluated by entering the interaction term as a covariate in logistic regression analysis. The additive interaction was assessed by Relative Excess Risk due to Interaction (RERI), Attributable Proportion due to interaction (AP) and Synergistic Index (SI) [35] using R statistics (Version 3.0.3, R foundation for Statistical Computing Platform). Unless specified, all analysis was performed using SPSS Statistics (version 22; IBM, USA).

**Results**

Of 19191 patients, the mean age was 58.1 ± 17.0 years and 52.4% were men. In total, 17.8% had hypertension, 20.3% had diabetes, 13.5% had cardiovascular disease, and 24.8% had cancer. In this population, 8.2% were hyponatremic initially. During a median (IQR) 6.0 (3.0–10.0) days of hospital stay, 5.1% experienced AKI of all stages, and 0.9% died from all causes within 90 days after admission. No patient died before the development of AKI. Among patients with the development of AKI or in-hospital mortality, the median (IQR) duration from the admission
date to the development of AKI and in-hospital mortality were 5.0 (2.0–10.0) days and 13.6 (6.7–27.3) days, respectively.

Characteristics of hyponatremia and AKI group

We compared baseline characteristics according to the status of hyponatremia (Table 1). Older age and male were associated with hyponatremia. Patients with hyponatremia showed higher proportions of hypertension, diabetes, and cancer, and a lower proportion of cardiovascular disease than those with normonatremia. RAS inhibitors and diuretics use were associated with hyponatremia. Hyponatremic patients had lower body mass index, systolic and diastolic blood pressure (BP) and higher serum glucose than normonatremic patients. Patients with

Table 1. Baseline characteristics of sodium group.

|                        | Normonatremia (n = 17624) | Hyponatremia (n = 1567) | P     |
|------------------------|---------------------------|-------------------------|-------|
| Age (years)            | 57.4 ± 16.9               | 65.4 ± 16.3             | < 0.001|
| Male sex               | 9156 (52.0)               | 908 (57.9)              | < 0.001|
| Hypertension           | 3022 (17.1)               | 395 (25.2)              | < 0.001|
| Diabetes               | 3317 (18.8)               | 570 (36.4)              | < 0.001|
| Cardiovascular disease | 2431 (13.8)               | 165 (10.5)              | < 0.001|
| Congestive heart failure| 147 (0.8)                | 27 (1.7)                | < 0.001|
| Liver disease          | 1061 (6.0)                | 143 (9.1)               | < 0.001|
| Cancer                 | 4229 (24.0)               | 538 (34.3)              | < 0.001|
| RAS inhibitor          | 1210 (6.9)                | 166 (10.6)              | < 0.001|
| Diuretics              | 705 (4.0)                 | 162 (10.3)              | < 0.001|
| Body mass index (kg/m²)*| 23.9 ± 3.6               | 22.3 ± 4                | < 0.001|
| Systolic BP (mmHg)*    | 130.7 ± 20.5              | 127.3 ± 22.3            | < 0.001|
| Diastolic BP (mmHg)*   | 75.6 ± 13.5               | 71.8 ± 14               | < 0.001|
| Sodium (mmol/L)        | 139.4 ± 2.2               | 131.2 ± 3.6             | < 0.001|
| Glucose (mmol/L)*      | 6.9 ± 2.6                 | 8.6 ± 5.2               | < 0.001|
| White blood cells (10⁹/μL)* | 8.2 ± 5.5           | 9.8 ± 7.2               | < 0.001|
| Hemoglobin (g/dL)*     | 12.8 ± 2                  | 11.7 ± 2.2              | < 0.001|
| Platelet (10⁹/μL)*     | 217.5 ± 77.6              | 223.8 ± 105.5           | 0.021|
| NLR*                   | 4.8 ± 5.2                 | 7.4 ± 7.9               | < 0.001|
| RDW (%)                | 13.6 ± 1.7                | 14.2 ± 2.2              | < 0.001|
| C-reactive protein (nmol/L)* | 467.6 ± 567.5  | 717.6 ± 697.8           | < 0.001|
| Protein (g/L)*         | 65.7 ± 7.9                | 63.4 ± 8.8              | < 0.001|
| Albumin (g/L)*         | 39.7 ± 5.7                | 35.2 ± 6.2              | < 0.001|
| Cholesterol (mmol/L)*  | 4.5 ± 1.2                 | 4.1 ± 1.5               | < 0.001|
| Bilirubin (μmol/L)*    | 13.8 ± 19.6               | 22.2 ± 43.1             | < 0.001|
| Blood urea nitrogen (mmol/L)* | 5.3 ± 2.5           | 6.0 ± 3.6               | < 0.001|
| Serum creatinine (μmol/L) | 78.4 ± 32.8             | 80.1 ± 55.6             | 0.248|
| eGFR (ml/min/1.73m²)   | 86.3 ± 18.5               | 83.8 ± 22.5             | < 0.001|

RAS, renin angiotensin system; BP, blood pressure; NLR, neutrophil to lymphocyte ratio; RDW, red cell distribution width; eGFR, estimated glomerular filtration rate.

Values are expressed as mean ± standard deviation for continuous variables and n (%) for categorical variables. Comparisons were made by chi square for categorical variables or Student t-test for continuous variables.

*Incomplete data. The missing data rate was 9.4% in body mass index, 0.3% in systolic and diastolic BP, 12.2% in glucose, 1.1% in white blood cells, hemoglobin and platelet, 30.2% in NLR and RDW, 44.4% in C-reactive protein, 2.2% in protein, 1.5% in albumin, 2.1% in cholesterol, 1.5% in bilirubin and 0.2% in blood urea nitrogen.

R:\10.1371\journal.pone.0162990.t001
Hyponatremia revealed significantly higher levels of inflammation, as indicated by white blood cells, NLR, RDW, and CRP, than those with normonatremia. Hemoglobin levels were significantly lower in the hyponatremic group than in the normonatremic group. Hyponatremic patients had lower eGFRs than normonatremic patients.

We also explored factors associated with AKI development (Table 2). Older age, male, and the presence of comorbidities were related to AKI development. RAS inhibitors and diuretics were associated with AKI development. Patients with AKI showed higher levels of serum glucose and inflammation than those without AKI. The AKI group had significantly lower levels of hemoglobin than the non-AKI group. Higher levels of blood urea nitrogen (BUN) were associated with AKI development. In multivariate Cox proportional hazard regression analysis, male, diabetes, congestive heart failure, diuretics use, diastolic BP, and levels of hemoglobin, protein, albumin, bilirubin, and BUN were associated with AKI development.

Hyponatremia, AKI and mortality

Hyponatremic patients showed significantly higher incidence rates of AKI than normonatremic patients (Fig 2). Patients with AKI had considerably lower serum sodium levels than patients without AKI (Table 2). After adjusting for covariates including age, male, hypertension, diabetes, congestive heart failure, cancer, RAS inhibitors, diuretics, body mass index, diastolic BP, white blood cells, hemoglobin, and serum levels of glucose, protein, albumin, cholesterol, bilirubin, and BUN, hyponatremia was independently associated with the increased risk of AKI development with HR 1.300 (95% CI, 1.086–1.555; \( P = 0.004 \)) in multivariate Cox proportional hazard regression.

Hyponatremic patients had considerably poorer patient survival rates than normonatremic patients (Fig 3A). Patients with AKI also showed significantly shorter patient survival times than those without AKI (Fig 3B). Both hyponatremia and AKI were significantly related to the increased risk of in-hospital mortality with HRs (95% CI) of 2.481 (1.381–4.459, \( P = 0.002 \)) and 7.338 (4.727–11.391, \( P < 0.001 \)) in multivariate Cox proportional hazard regression analysis (Table 3). Since hyponatremia was related to AKI development, we explored the interaction between hyponatremia and AKI for the development of in-hospital mortality (Table 4). Compared to the patients with normonatremia and no AKI, patients with pre-existing hyponatremia and patients with AKI had worse in-hospital mortality (OR 7.515, \( P < 0.001 \); OR 45.69, \( P < 0.001 \), respectively) (Table 4). Pre-existing hyponatremia and subsequent development of AKI increased the risk of short-term mortality by 85.55 times, compared to the controls, although not statistically significant in RERI. We compared patient survival for different sodium levels and the presence of AKI (Fig 3C).

The hyponatremia & non-AKI, normonatremia & AKI, and hyponatremia & AKI groups showed significantly poorer patient survival than the normonatremia & non-AKI group. This was still evident in multivariate Cox proportional hazard regression analysis adjusting for the same variables in Table 3. HRs (95% CI) for the hyponatremia & non-AKI, normonatremia & AKI, and hyponatremia & AKI groups vs. the normonatremia & non-AKI group for the in-hospital mortality were 2.481 (1.381–4.458, \( P = 0.002 \)), 7.338 (4.727–11.391, \( P < 0.001 \)) and 7.951 (4.677–13.515, \( P < 0.001 \)), respectively.

As one of the overcorrection variables, we evaluated de novo hypernatremia. Of 18353 patients who had serial data of serum sodium levels, we found 405 patients with de novo hypernatremia (2.1%). De novo hypernatremia was also significantly associated with in-hospital mortality with HR 3.297 (95% CI 2.264–4.800, \( P < 0.001 \)) in a multivariate Cox proportional hazard regression model. Meanwhile, patients with AKI (16.2%) showed significantly higher rates of de novo hypernatremia than patients without AKI (1.4%; \( P < 0.001 \)). Through
### Table 2. Factors associated with acute kidney injury development.

|                          | Non-AKI (n = 18215) | AKI (n = 976) | P     | HR (95% CI) | P     |
|--------------------------|---------------------|--------------|-------|-------------|-------|
| Age (years)‡             | 58.7 ± 17.0         | 65.3 ± 15.6  | < 0.001 | 1.118 (0.954–1.310) | 0.168 |
| Male sex                 | 9501 (52.2)         | 563 (57.7)   | 0.001 | 1.262 (1.088–1.465) | 0.002 |
| Hypertension             | 3148 (17.3)         | 269 (27.6)   | < 0.001 | 1.015 (0.822–1.253) | 0.891 |
| Diabetes                 | 3449 (18.9)         | 438 (44.9)   | < 0.001 | 1.885 (1.622–2.192) | < 0.001 |
| Cardiovascular disease   | 2445 (13.4)         | 151 (15.5)   | 0.068 | -           | -     |
| Congestive heart failure | 129 (0.7)           | 45 (4.6)     | < 0.001 | 2.986 (2.072–4.303) | < 0.001 |
| Liver disease            | 1136 (6.2)          | 68 (7.0)     | 0.359 | -           | -     |
| Cancer                   | 4443 (24.4)         | 324 (33.2)   | < 0.001 | 1.026 (0.786–1.340) | 0.850 |
| RAS inhibitor            | 1269 (7.0)          | 107 (11.0)   | < 0.001 | 1.026 (0.786–1.340) | 0.850 |
| Diuretics                | 754 (4.1)           | 113 (11.6)   | < 0.001 | 1.514 (1.151–1.993) | 0.003 |
| Body mass index (kg/m²)* | 23.8 ± 3.7          | 23.2 ± 4.0   | < 0.001 | 1.000 (0.982–1.018) | 0.991 |
| Systolic BP (mmHg)*      | 130.4 ± 20.4        | 130.9 ± 25.0 | 0.562 | -           | -     |
| Diastolic BP (mmHg)*     | 75.4 ± 13.5         | 74 ± 15.2    | 0.006 | 1.006 (1.001–1.011) | 0.016 |
| Hyponatremia             | 1366 (7.5)          | 201 (20.6)   | < 0.001 | 1.300 (1.086–1.555) | < 0.001 |
| Sodium (mmol/L)‡         | 138.8 ± 3.1         | 137.1 ± 4.0  | < 0.001 | 1.000 (0.982–1.018) | 0.991 |
| Glucose (mmol/L)*‡       | 7.0 ± 2.9           | 8.0 ± 4.1    | < 0.001 | 1.030 (0.890–1.192) | 0.695 |
| WBC (10³/μL)*           | 8.3 ± 5.5           | 9.5 ± 7.7    | < 0.001 | 1.006 (0.997–1.014) | 0.185 |
| Hemoglobin (g/dL)*       | 12.8 ± 2.0          | 11.8 ± 2.3   | < 0.001 | 0.959 (0.921–0.998) | 0.038 |
| Platelet (10³/μL)*‡      | 218.2 ± 78.6        | 214.2 ± 105.6 | 0.247 | -           | -     |
| NLR*‡                   | 4.9 ± 5.3           | 7.3 ± 8.7    | < 0.001 | -           | -     |
| RDW (%)*                | 13.6 ± 1.8          | 14.3 ± 1.9   | < 0.001 | -           | -     |
| CRP (nmol/L)*            | 482.9 ± 578.5       | 628.0 ± 674.2 | < 0.001 | -           | -     |
| Protein (g/L)*           | 65.6 ± 7.9          | 63.1 ± 9.0   | < 0.001 | 1.013 (1.003–1.023) | 0.012 |
| Albumin (g/L)*           | 39.5 ± 5.8          | 35.8 ± 6.6   | < 0.001 | 0.948 (0.930–0.964) | < 0.001 |
| Cholesterol (mmol/L)*‡   | 4.5 ± 1.2           | 4.1 ± 1.4    | < 0.001 | 1.072 (0.917–1.253) | 0.385 |
| Bilirubin (μmol/L)*      | 14.0 ± 19.9         | 23.7 ± 50.5  | < 0.001 | 1.003 (1.001–1.004) | < 0.001 |
| BUN (mmol/L)*‡           | 5.3 ± 2.5           | 7.0 ± 4.5    | < 0.001 | 1.559 (1.352–1.798) | < 0.001 |
| Serum creatinine (μmol/L)| 78.3 ± 31.3         | 82.7 ± 78.1  | 0.082 | -           | -     |
| eGFR (ml/min/1.73m²)‡    | 86.1 ± 18.2         | 86.0 ± 28.9  | 0.201 | -           | -     |
| eGFR > 86.1 ml/min/17.3m² | 7725 (42.4)       | 430 (44.1)   | 0.310 | -           | -     |
| eGFR (min.–max.)         | 2.4–210.4           | 3.4–193.2    | -     | -           | -     |

HR, hazard ratio; CI, confidence interval; RAS, renin angiotensin system; BP, blood pressure; WBC, white blood cells; NLR, neutrophil to lymphocyte ratio; RDW, red cell distribution width; CRP, c-reactive protein; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate.

Values are expressed as mean ± standard deviation for continuous variables and n (%) for categorical variables. Comparisons were made by chi-square test for categorical variables or Student t-test for continuous variables. HRs for categorical and continuous variables were "yes vs. no" and "per 1 unit increase", respectively.

* Incomplete data. The missing data rate was 9.4% in body mass index, 0.3% in systolic and diastolic BP, 12.2% in glucose, 1.1% in white blood cells, hemoglobin and platelet, 30.2% in NLR and RDW, 44.4% in CRP, 2.2% in protein, 1.5% in albumin, 2.1% in cholesterol, 1.5% in bilirubin and 0.2% in BUN.

† Cox proportional hazard regression analysis entering variables with \( P < 0.05 \) in univariate analysis and missing rate < 15%.

‡ Not fulfilling the proportional hazard assumption as continuous variables, but fulfilling the assumption as categorical variables by their mean value in whole patients: 58.7 years for age, 7.1 mmol/L for glucose, 5.3 for NLR, 4.4 mmol/L for cholesterol, and 6.0 mmol/L for BUN. The reported HRs were above vs. below the mean.

§ Mean of eGFR in whole population.

doi:10.1371/journal.pone.0162990.t002
examining different combinations of sodium levels and AKI, we identified a significant tendency of an increased rate of de novo hypernatremia across the normonatremia & non-AKI, hyponatremia & non-AKI, normonatremia & AKI and hyponatremia & AKI groups (Fig 4). Hyponatremic patients also showed a significantly higher risk of severe AKI, 1-year ESRD, and 1-year mortality than normonatremic patients (Fig 2).

Effect of hyponatremia correction

Of 18353 patients who had serial data on serum sodium levels, 84.5%, 3.1%, 2.2% and 5.9% were classified as persistent normonatremia, de novo hyponatremia, corrected hyponatremia, and persistent hyponatremia groups, respectively. Patients with persistent normonatremia showed consistently lower risks of AKI development and in-hospital mortality than those with corrected hyponatremia. Patients with de novo hyponatremia still had a lower risk of in-hospital mortality than those with corrected hyponatremia. The risks of AKI development and in-hospital mortality were not different between patients with persistent and corrected hyponatremia (Table 5).

Discussion

Hyponatremia in hospitalized patients is common [1, 36], and may increase the risk of mortality in various conditions. AKI is a common and dangerous, but correctable, disease. The two clinical conditions may share various comorbidities, and there is a high chance of cross-talk among hyponatremia, AKI and mortality. Therefore, we investigated whether pre-existing hyponatremia may be associated with the development of AKI during the hospital stay. We
also evaluated whether hospital acquired AKI modified the effect of hyponatremia on short-term patients mortality.

One of the major findings is that hyponatremic patients have approximately a 1.3-fold higher risk of AKI development than normonatremic patients. Sodium levels reflect on the homeostasis of water regulation in the body [1, 20]. Hyponatremia may be related to unbalanced condition of extracellular water, major organ failure or septic conditions [1, 3, 4, 37], which are some of main causes in hospital acquired AKI [13–18]. The higher rates of AKI risk factors [38] in hyponatremic patients than in normonatremic patients might affect the association between hyponatremia and AKI development. In addition, the higher levels of inflammation found in hyponatremic patients might explain the increased risk of AKI development with hyponatremia. With our study, we cannot conclude whether hyponatremia has causal relationship for the AKI development or not. However, we postulate hyponatremia might be a simple “association”, not a causative factor for AKI development since patients with persistent normonatremia showed lower risk for AKI development than patients with corrected hyponatremia. Although further study is needed to confirm this result, one thing which can be stated is that patients with pre-existing hyponatremia may need to be periodically monitored with serum creatinine levels or urine outputs for AKI development.

Fig 3. Cumulative survival rate according to sodium (Na) and acute kidney injury (AKI) groups. A, B and C show survival curves of sodium, AKI and combined sodium and AKI groups for the in-hospital mortality, respectively. * and † indicate $P < 0.001$ when compared to normonatremic patients without AKI and hyponatremic patients without AKI groups, respectively, and ‡ indicates $P < 0.05$ when compared to normonatremic with AKI group using log-rank test.

doi:10.1371/journal.pone.0162990.g003
We observed that hyponatremia is an independent risk factor for in-hospital mortality (HR 2.481). Hyponatremia can influence on patient mortality [20]. However, if there would be some interaction between hyponatremia and AKI, these two combined pathologic conditions could contribute to dramatic increase in fatal outcomes. Since hyponatremia is tightly associated with AKI development and AKI is significantly associated with an increased risk of in-hospital mortality (HR 7.338) in our data, we examined whether there was a combined effect of hyponatremia and hospital acquired AKI on in-hospital mortality. In terms of clinical practice, it may be difficult to control patients homeostasis of electrolyte and fluid in patients with AKI.

Table 3. Hazard ratio for in-hospital mortality in Cox proportional hazard regression.

|                      | Univariate      | Multivariate    |
|----------------------|-----------------|-----------------|
|                      | HR (95% CI)     | P               | HR (95% CI)     | P               |
| Age (years)          | 1.044 (1.032–1.056) | < 0.001         | 1.025 (1.011–1.039) | < 0.001         |
| Male sex             | 1.339 (0.987–1.818) | 0.061           | -               | -               |
| Hypertension         | 1.742 (1.262–2.405) | 0.001           | 1.034 (0.627–1.707) | 0.895           |
| Diabetes             | 2.351 (1.731–3.192) | < 0.001         | 1.140 (0.793–1.639) | 0.479           |
| Cardiovascular disease | 2.177 (1.540–3.077) | < 0.001         | 2.209 (1.428–3.416) | < 0.001         |
| Congestive heart failure | 3.801 (1.869–7.729) | < 0.001         | 0.743 (0.285–1.939) | 0.544           |
| Liver disease        | 1.106 (0.565–2.165) | 0.768           | -               | -               |
| Cancer               | 1.654 (1.225–2.233) | 0.001           | 1.916 (1.331–2.758) | < 0.001         |
| RAS inhibitor        | 1.751 (1.087–2.820) | 0.021           | 0.915 (0.500–1.674) | 0.774           |
| Diuretics            | 3.293 (2.155–5.031) | < 0.001         | 1.543 (0.829–2.873) | 0.171           |
| BMI ≥ 23.7 kg/m²†    | 0.393 (0.270–0.571) | < 0.001         | 0.500 (0.341–0.734) | < 0.001         |
| SBP > 130.2 mmHg†    | 0.659 (0.485–0.897) | 0.008           | 0.666 (0.455–0.975) | 0.037           |
| DBP ≥ 74.9 mmHg†     | 0.627 (0.462–0.852) | 0.003           | 1.138 (0.784–1.652) | 0.497           |
| Glucose (mmol/L)     | 1.072 (1.042–1.103) | < 0.001         | 1.007 (0.965–1.051) | 0.746           |
| WBC (10⁹/μL)         | 1.020 (1.013–1.026) | < 0.001         | 1.017 (1.007–1.027) | 0.001           |
| Hemoglobin (g/dL)    | 0.849 (0.796–0.906) | < 0.001         | 1.047 (0.959–1.143) | 0.308           |
| Platelet (10⁹/μL)    | 0.996 (0.994–0.998) | < 0.001         | 0.998 (0.996–0.999) | 0.009           |
| NLR*                 | 1.037 (1.028–1.046) | < 0.001         | -               | -               |
| RDW (%)*             | 1.232 (1.174–1.293) | < 0.001         | -               | -               |
| CRP (mmol/L)*        | 1.001 (1.001–1.001) | < 0.001         | -               | -               |
| Protein (g/L)        | 0.964 (0.949–0.979) | < 0.001         | 1.005 (0.984–1.026) | 0.625           |
| Albumin ≥ 39 g/L†    | 0.290 (0.200–0.420) | < 0.001         | 0.456 (0.279–0.746) | 0.002           |
| Cholesterol (mmol/L) | 0.664 (0.580–0.759) | < 0.001         | 0.869 (0.757–0.997) | 0.045           |
| Bilirubin (μmol/L)   | 1.003 (1.001–1.006) | 0.004           | 1.002 (1.000–1.005) | 0.088           |
| BUN ≥ 6.0 mmol/L†    | 2.730 (2.009–3.708) | < 0.001         | 1.301 (0.915–1.850) | 0.143           |
| eGFR (ml/min/1.73m²) | 0.993 (0.987–1.000) | 0.051           | -               | -               |
| Hyponatremia         | 2.915 (2.121–4.006) | < 0.001         | 2.481 (1.381–4.459) | 0.002           |
| AKI                  | 8.711 (6.273–12.097) | < 0.001         | 7.338 (4.727–11.391) | < 0.001         |

HR, hazard ratio; CI, confidence interval; RAS, renin angiotensin system; BP, blood pressure; WBC, white blood cells; NLR, neutrophil to lymphocyte ratio; RDW, red cell distribution width; CRP, c-reactive protein; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; AKI, acute kidney injury.

HRs for categorical and continuous variables were “yes vs. no” and “per 1 unit increase”, respectively. Interaction term between hyponatremia and AKI was statistically significant in both univariate (P = 0.001) and multivariate (P = 0.024) analysis. Variables with P < 0.05 in univariate analysis and missing rate < 15.0% were entered into multivariate analysis.

* Missing rate >15.0%
† Not fulfilling the proportional hazard assumption as continuous variables, but fulfilling the assumption as categorical variables by their mean value in whole patients.

doi:10.1371/journal.pone.0162990.t003
Table 4. Interaction analysis between hyponatremia and acute kidney injury for the in-hospital mortality.

|                  | AKI |                  |                  |
|------------------|-----|------------------|------------------|
|                  | No  | OR (95% CI)      | Yes             | OR (95% CI)      |
|                  | N*  |                  | N*              |                  |
| Hyponatremia     |     |                  |                 |                  |
| No               | 40/16809 | 1.0 (reference) | 76/699         | 45.690 (30.926–67.501) |
| Yes              | 24/1342   | 7.515 (4.517–12.504) | 85.554 (52.838–138.529) | 11.384 (6.590–19.667) |
| OR (95% CI) for hyponatremia (yes vs. no) within strata of AKI group | 7.515 (4.517–12.504) | 1.873 (1.208–2.902) |

Measure of interaction on additive scale: RERI (95% CI) 33.350 (-1.611–68.311), AP (95% CI) 0.390 (0.129–0.650) and SI (95% CI) 1.651 (1.071–2.546); Measure of interaction on multiplicative scale: OR (95% CI) 0.249 (0.127–0.488). ORs are unadjusted. OR, odd ratio; CI, confidence interval; AKI, acute kidney injury; RERI, relative excess risk due to interaction; AP, attributable proportion due to interaction; SI, synergistic index.

*with/without in-hospital mortality

doi:10.1371/journal.pone.0162990.t004

Fig 4. Proportion of de novo hypernatremia depending on the status of combined sodium (Na) and acute kidney injury (AKI) group. Error bar indicates standard error. * indicates P < 0.05 by chi-square test when compared to the normoNa & non-AKI group.

doi:10.1371/journal.pone.0162990.g004
which could be a potential explanation of this combined interaction between hyponatremia and AKI. We observed that the serum sodium level fluctuated more in patients with AKI than in those without AKI, since the AKI group showed higher rates of de novo hypernatremia than the non-AKI group by 11.6 fold. We also identified that patients with de novo hypernatremia showed a 3.297 times higher risk of in-hospital mortality than patients without de novo hypernatremia. Therefore it may demonstrate that the unstable sodium homeostasis in the AKI group could explain the combined effect between hyponatremia and AKI for in-hospital mortality.

Up to now, it has been uncertain whether patients die with or from hyponatremia. One meta-analysis suggested that the improvement of hyponatremia would revert or decrease the mortality risk related to hyponatremia [39]. However, not all the literature in the meta-analysis compared the corrected hyponatremia groups with persistent normonatremia. In fact, some studies clearly showed that the resolution of hyponatremia did not reduce the mortality risk [40–42], which is consistent with our results. Corrected hyponatremia did not reduce the risk of in-hospital mortality compared to persistent or de novo hyponatremia. The risk of in-hospital mortality between patients with corrected and persistent hyponatremia were similar. Therefore, further well-designed trials are still needed whether hyponatremia might be a bystander or a causative factor for in-hospital mortality.

There are some strengths of this study. First, the results were drawn from a very large administrative cohort. Second, all patients who admitted in this tertiary hospital were enrolled which minimized a selection bias. In addition, the clinical and laboratory data from the enrolled patients were available with low missing rate. Finally, we defined a baseline creatinine with the values 6 months before the admission which was not always possible in this large cohort study. However, the current study also has several limitations. First, we could not use glucose-adjusted serum sodium since not all patients had serum glucose assessed at the same time as serum sodium. Generally, every 100 mg/dL increase of serum glucose results in 2.4 mmol/L decrease of serum sodium levels [1]. However, the serum glucose levels of the study patients were not very high. Moreover, we used the serum glucose level as a covariate in multivariate analysis. Therefore, the effect of serum glucose on our study result should be minimal. Second, we defined AKI only by the creatinine criteria since not all patients had urine output recorded. Third, since this was retrospective, there were some uncertainties in information. We had little information on causes of AKI and death. Among patients with community acquired AKI who were excluded from this analysis, significant proportion of patients could be CKD patients. There is a chance to have other unmeasured confounders. Finally, the generalizability might be limited because this was a single-nation and single-center study.

Table 5. Hazard ratio of hyponatremia correction group for the development of acute kidney injury and in-hospital mortality in multivariate Cox proportional hazard regression analysis.

|               | For AKI development |          | For in-hospital mortality |          |
|---------------|---------------------|----------|---------------------------|----------|
|               | HR (95% CI)         | P        | HR (95% CI)               | P        |
| vs. Corrected hyponatremia |                     |          |                           |          |
| Persistent normonatremia     | 0.606 (0.457–0.803) | < 0.001  | 0.514 (0.312–0.846)       | 0.009    |
| De novo hyponatremia          | 0.894 (0.643–1.242) | 0.505    | 0.504 (0.264–0.964)       | 0.038    |
| Persistent hyponatremia       | 0.793 (0.578–1.088) | 0.151    | 0.590 (0.327–1.065)       | 0.080    |

AKI, acute kidney injury; HR, hazard ratio; CI, confidence interval.
Variables with P < 0.05 in univariate analysis and missing rate < 15.0% were entered into the analysis. All covariates entered fulfilled the assumption of proportional hazard.

doi:10.1371/journal.pone.0162990.t005
We found that pre-existing hyponatremia may predict the development of AKI and in-hospital mortality, and that hyponatremia and AKI may lead to combined bad consequences such as in-hospital mortality, probably related to the unstable sodium homeostasis during the treatment period of hospital stay. It will be a possible option to reduce patient’s event that hyponatremic patients need to monitor the development of AKI more frequently and to avoid overcorrection of hyponatremia in AKI patients.

Author Contributions
Conceived and designed the experiments: SWL SHB SK.
Performed the experiments: SWL SYA KYN.
Analyzed the data: SWL D-WC HJC.
Wrote the paper: SWL SK.

References
1. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, et al. Clinical practice guideline on diagnosis and treatment of hyponatremia. Eur J Endocrinol. 2014; 170(3):G1–47. doi: 10.1530/EJE-13-1020 PMID: 24569125.
2. Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med. 2010; 170(3):294–302. doi: 10.1001/archinternmed.2009.513 PMID: 20142578.
3. Saepudin S, Ball PA, Morrissey H. Hyponatremia during hospitalization and in-hospital mortality in patients hospitalized from heart failure. BMC Cardiovasc Disord. 2015; 15:88. doi: 10.1186/s12872-015-0082-5 PMID: 26271263; PubMed Central PMCID: PMC4542119.
4. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008; 359(10):1018–26. doi: 10.1056/NEJMoa0801209 PMID: 18768945; PubMed Central PMCID: PMC374557.
5. Kuramatsu JB, Bobinger T, Volbers B, Staykov D, Lucking H, Kloska SP, et al. Hyponatremia is an independent predictor of in-hospital mortality in spontaneous intracerebral hemorrhage. Stroke. 2014; 45(5):1285–91. doi: 10.1161/STROKEAHA.113.004136 PMID: 24713534.
6. Chang TI, Kim YL, Kim H, Ryu GW, Kang EW, Park JT, et al. Hyponatremia as a predictor of mortality in peritoneal dialysis patients. PloS one. 2014; 9(10):e111373. doi: 10.1371/journal.pone.0111373 PMID: 25354265; PubMed Central PMCID: PMC4213027.
7. Nigwekar SU, Wenger J, Thadhani R, Bhan I. Hyponatremia, mineral metabolism, and mortality in incident maintenance hemodialysis patients: a cohort study. Am J Kidney Dis. 2013; 62(4):755–62. doi: 10.1053/ajkd.2013.02.367 PMID: 23591291; PubMed Central PMCID: PMC3592035.
8. Corona G, Giuliani C, Parenti G, Norello D, Verbalis JG, Forti G, et al. Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis. PloS one. 2013; 8(12):e80451. doi: 10.1371/journal.pone.0080451 PMID: 24367479; PubMed Central PMCID: PMC3867320.
9. Kellum JA, Lameire N, Group KAGW. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013; 17(1):204. doi: 10.1186/cc11454 PMID: 23934211; PubMed Central PMCID: PMC4057151.
10. Kinsella S, Moran S, Sullivan MO, Molloy MG, Eustace JA. Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol. 2010; 5(2):275–80. doi: 10.2215/CJN.06120809 PMID: 20056759; PubMed Central PMCID: PMC2827801.
11. Lee SW, Yu MY, Lee H, Ahn SY, Kim S, Chin HJ, et al. Risk Factors for Acute Kidney Injury and In-Hospital Mortality in Patients Receiving Extracorporeal Membrane Oxygenation. PloS one. 2015; 10(10):e0140674. doi: 10.1371/journal.pone.0140674 PMID: 26469793.
12. Ali T, Khan I, Simpson W, Prescott G, Townend J, Smith W, et al. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol. 2007; 18(14):1292–8. Epub 2007/02/23. ASN.2006070756 [pii] doi: 10.1681/ASN.2006070756 PMID: 17314324.
13. Doi K, Katagiri D, Negishi K, Hasegawa S, Harnasaki Y, Fujita T, et al. Mild elevation of urinary biomarkers in prerenal acute kidney injury. Kidney Int. 2012; 82(10):1114–20. doi: 10.1038/ki.2012.266 PMID: 22854644.
14. Grams ME, Estrella MM, Coresh J, Brower RG, Liu KD, National Heart L, et al. Fluid balance, diuretic use, and mortality in acute kidney injury. Clin J Am Soc Nephrol. 2011; 6(5):966–73. doi: 10.2215/CJN.08781010 PMID: 21393482; PubMed Central PMCID: PMC3087792.

15. Wang N, Jiang L, Zhu B, Wen Y, Xi XM, Beijing Acute Kidney Injury Trial W. Fluid balance and mortality in critically ill patients with acute kidney injury: a multicenter prospective epidemiological study. Crit care. 2015; 19(1):371. doi: 10.1186/s13054-015-1085-4 PMID: 26494153; PubMed Central PMCID: PMC4619072.

16. Shum HP, Yan WW, Chan TM. Recent knowledge on the pathophysiology of septic acute kidney injury: A narrative review. J Crit Care. 2016; 31(1):82–9. doi: 10.1016/j.jcrc.2015.09.017 PMID: 26475099.

17. Braam B, Joles JA, Danishvar AH, Gaillard CA. Cardiorenal syndrome—current understanding and future perspectives. Nat Rev Nephrol. 2014; 10(1):48–55. doi: 10.1038/nrneph.2013.250 PMID: 24247284.

18. Shum HP, Yan WW, Chan TM. Recent knowledge on the pathophysiology of septic acute kidney injury: A narrative review. J Crit Care. 2016; 31(1):82–9. doi: 10.1016/j.jcrc.2015.09.017 PMID: 26475099.

19. Adrogue HJ, Madias NE. Hyponatraemia. N Engl J Med. 2000; 342(21):1581–9. doi: 10.1056/NEJM2000051834220107 PMID: 10824078.

20. Hoorn EJ, Zietse R. Hyponatraemia and mortality: moving beyond associations. Am J Kidney Dis. 2013; 62(1):139–49. doi: 10.1053/ajkd.2012.09.019 PMID: 23291150.

21. Bodonyi-Kovacs G, Lecker SH. Electrolyte-free water clearance: a key to the diagnosis of hypernatremia in resolving acute renal failure. Clin Exp Nephrol. 2008; 12(1):74–8. doi: 10.1007/s10157-007-0021-6 PMID: 18180873.

22. Mehta RL, Bouchard J. Controversies in acute kidney injury: effects of fluid overload on outcome. Contrib Nephrol. 2011; 174:200–11. doi: 10.1159/000329410 PMID: 21921625.

23. Aoronson D, Darawsha W, Promyslovsky M, Kaplan M, Abassi Z, Makhoul BF, et al. Hyponatraemia predicts the acute (type 1) cardio-renal syndrome. Eur J Heart Fail. 2014; 16(1):49–55. doi: 10.1093/eurjhf/hft123 PMID: 23883652.

24. Lameire N, Van Biesen W, Vanholder R. Electrolyte disturbanc es and acute kidney injury in patients with cancer. Semin Nephrol. 2010; 30(6):534–47. doi: 10.1016/j.s emnephrol.2010.09.002 PMID: 21146119.

25. Hackworth WA, Heuman DM, Sanyal AJ, Fisher RA, Sterling RK, Luketic VA, et al. Effect of hyponatremia on outcomes following orthotopic liver transplantation. Liver Int. 2009; 29(7):1071–7. doi: 10.1111/j.1478-3231.2009.01982.x PMID: 19302181.

26. Adams D, de Jonge R, van der Cammen T, Zietse R, Hoorn EJ. Acute kidney injury in patients presenting with hyponatremia. J Nephrol. 2011; 24(6):749–55. doi: 10.5301/ajkd.2012.08.015 PMID: 23146154.

27. Liborio AB, Silva GB Jr., Silva CG, Lima Filho FJ, Studart Neto A, Okoba W, et al. Hyponatremia, acute kidney injury, and mortality in HIV-related toxoplasmic encephalitis. Braz J Infect Dis. 2012; 16(6):558–63. doi: 10.1016/j.bjid.2012.08.015 PMID: 23883652.

28. Madsen CM, Jantzen C, Lauritzen JB, Abrahamsen B, Jorgensen HL. Hyponatremia and hypernatremia are associated with increased 30-day mortality in hip fracture patients. Osteoporos Int. 2016; 27(1):397–404. doi: 10.1007/s00198-015-3423-4 PMID: 26576542.

29. Prats-Puig A, Gispert-Sau 1 M, Diaz-Roldan F, Carreras-Badosa G, Osiniri I, Planella-Colomer M, et al. Neutrophil-to-lymphocyte ratio: an inflammation marker related to cardiovascular risk in children. Thromb Haemost. 2015; 114(4):727–34. doi: 10.1160/TH15-01-0037 PMID: 26224329.

30. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000; 342(20):1493–9. doi: 10.1056/NEJM200005183422006 PMID: 10816188.

31. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604–12. Epub 2009/05/06. 150/9/604 [pii] PMID: 19414839; PubMed Central PMCID: PMC2763564.

32. Thomas ME, Blaine C, Dawsnay A, Devonald MA, Flouh S, Laing C, et al. The definition of acute kidney injury and its use in practice. Kidney Int. 2015; 87(1):62–73. Epub 2014/10/16. ki2014328 [pii] doi: 10.1038/ki.2014.328 PMID: 25317932.

33. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012; 2(1):1–138. Epub 2012/03/01. PubMed Central PMCID: PMC4086595.

34. McGregor TL, Jones DP, Wang L, Danciu I, Bridges BC, Fleming GM, et al. Acute Kidney Injury Incidence in Noncritically Ill Hospitalized Children, Adolescents, and Young Adults: A Retrospective Observational Study. Am J Kidney Dis. 2016; 67(3):384–90. doi: 10.1053/j.ajkd.2015.07.019 PMID: 26319754; PubMed Central PMCID: PMC4769119.
35. Rothman KJ. Synergy and antagonism in cause-effect relationships. Am J Epidemiol. 1974; 99(6):385–8. PMID: 4841816.
36. Elmi G, Zaccaroni S, Arienti V, Faustini-Fustini M. Prevalence and in-hospital mortality of hyponatremia: a cohort study. Eur J Intern Med. 2014; 25(4):e45–6. doi: 10.1016/j.ejim.2014.03.013 PMID: 24731782.
37. Riikonen P, Saarinen UM, Perkkio M, Hovi L, Siimes MA. Changing pattern of treatment policies invalidates the use of C-reactive protein level and hyponatremia as indicators of sepsis in children with malignancies. Pediatr Hematol Oncol. 1992; 9(4):365–72. PMID: 1467170.
38. Grams ME, Sang Y, Ballew SH, Gansevoort RT, Kimm H, Kovesdy CP, et al. A Meta-analysis of the Association of Estimated GFR, Albuminuria, Age, Race, and Sex With Acute Kidney Injury. Am J Kidney Dis. 2015; 66(4):591–601. doi: 10.1053/j.ajkd.2015.02.337 PMID: 25943717; PubMed Central PMCID: PMC4584180.
39. Corona G, Giuliani C, Verbali S JG, Forti G, Maggi M, Peri A. Hyponatremia improvement is associated with a reduced risk of mortality: evidence from a meta-analysis. PloS one. 2015; 10(4):e0124105. doi: 10.1371/journal.pone.0124105 PMID: 25905459; PubMed Central PMCID: PMC4408113.
40. Lee SE, Choi DJ, Yoon CH, Oh IY, Jeon ES, Kim JJ, et al. Improvement of hyponatraemia during hospitalisation for acute heart failure is not associated with improvement of prognosis: an analysis from the Korean Heart Failure (KorHF) registry. Heart. 2012; 98(24):1798–804. doi: 10.1136/heartjnl-2012-302334 PMID: 23125248.
41. Gheorghidae M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Pina IL, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med. 2007; 167(18):1998–2005. doi: 10.1001/archinte.167.18.1998 PMID: 17923601.
42. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med. 2009; 122(9):857–65. doi: 10.1016/j.amjmed.2009.01.027 PMID: 19699382; PubMed Central PMCID: PMC3033702.